Overall rank by patents
#44,586
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
Aprevent holds 5 US patents across 3 technology areas, rank #44,586 of 50,000 tracked assignees.
Aprevent Medical Inc. has been granted 5 US utility patents between 2017 and 2025, placing Aprevent Medical Inc. at rank #44,586 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.2 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, Aprevent Medical Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Aprevent sits between Apollo FIRE Detectors Limited (5 patents, rank #44,582) and AQUA Conscience Holdings Llc (5 patents, rank #44,590) - the closest US assignees by grant volume. The composite Innovation Score of 24.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 2 in the 2015–2019 window, a +50% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Aprevent Medical Inc.'s 15.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Aprevent Medical Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
APOLLO FIRE DETECTORS LIMITED
5 patents
APPLESTONE MEAT COMPANY LLC
5 patents
APPLIED RESEARCH CENTER
5 patents
APR Technologies AB
5 patents
APRIORI TECHNOLOGIES INC.
5 patents
APSE, INC.
5 patents
APT ELECTRONICS CO., LTD.
5 patents
AQUA CONSCIENCE HOLDINGS LLC
5 patents
APREVENT MEDICAL INC.
5 patents
What this shows Aprevent holds 5 patents at rank #44,586, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,586 in granted patent volume.
Other assignees with the most granted patents in Aprevent's primary technology class.
Aprevent's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
25 Top 85% higher than 15% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 20.0% |
| 2019 | 1 | 20.0% |
| 2020 | 1 | 20.0% |
| 2024 | 1 | 20.0% |
| 2025 | 1 | 20.0% |
Top 3 of 3 technology areas
Overall rank by patents
#44,586
Across all tracked assignees
24.8 out of 100
How to use this portfolio
Aprevent's 5 grants land it in the top 85% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.